Stay updated with breaking news from Mohamed Eid. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- Jardiance® (empagliflozin) reduced the risk for the composite primary endpoint of cardiovascular death or hospitalization for heart failure and...
Boehringer Ingelheim and Eli Lilly and Company (NYSE:LLY) today announced the launch of CRMSynced™, an educational initiative that uses gamification to encourage healthcare professionals (HCPs) to prioritize a holistic approach to care for cardio-renal-metabolic (C-R-M) conditions. Accounting for up to 20 million ...
Boehringer Ingelheim and Eli Lilly and Company today announced the launch of CRMSynced ™ an educational initiative that uses gamification to encourage healthcare professionals to prioritize a holistic approach to care for cardio-renal-metabolic conditions. Accounting for up to 20 million deaths in the U.S. annually, C-R-M conditions, including diabetes, heart disease and chronic kidney disease, are the leading ...
The approval was based on data from the phase 3 EMPEROR-Reduced trial.
The US FDA has approved Boehringer Ingelheim and Eli Lilly's Jardiance (empagliflozin) to treat Heart Failure with reduced Ejection Fraction (HFrEF).